BioCentury | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

...deubiquitinase (DUB) inhibitors, mostly to treat cancer and neurodegenerative diseases. While one -- VLX1570 from Vivolux AB...
...AML); chronic lymphocytic leukemia (CLL) Preclinical Ubiquitin specific peptidase 14 tRNA-guanine transglycosylase (USP14: TGT) inhibitors Vivolux AB...
BioCentury | Mar 3, 2014
Clinical News

Vivolux preclinical data

...or total protein. Additionally, in vitro, VLX600 reduced the viability of quiescent tumor cells, which Vivolux...
...in June. VLX600 is a small molecule that inhibits mitochondrial oxidative phosphorylation in hypoglycemic cells. Vivolux AB...
BioCentury | Dec 8, 2011
Targets & Mechanisms

Proteasome DUBstep

...inhibitor for cancer that has a distinct mechanism from other compounds in the class. 1 Vivolux AB...
...peptidase 7 ( USP7 ; HAUSP ) that is in preclinical development for cancer. Viva Vivolux...
...the sale, Ågerup's holding company, Lyftet Holding, owned 47.5% of Q-Med. Hans Rosén, CEO of Vivolux...
BioCentury | Nov 17, 2011
Distillery Therapeutics

Indication: Cancer

...solid tumors. SciBX 4(45); doi:10.1038/scibx.2011.1262 Published online Nov. 17, 2011 Patent application filed; licensed to Vivolux AB...
BioCentury | Nov 14, 2011
Financial News

Vivolux completes venture financing

Vivolux AB , Uppsala, Sweden Business: Cancer Date completed: 11/7/11 Type: Venture financing Raised: Not disclosed Investor: NXT2B WIR Staff cancer...
Items per page:
1 - 5 of 5
BioCentury | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

...deubiquitinase (DUB) inhibitors, mostly to treat cancer and neurodegenerative diseases. While one -- VLX1570 from Vivolux AB...
...AML); chronic lymphocytic leukemia (CLL) Preclinical Ubiquitin specific peptidase 14 tRNA-guanine transglycosylase (USP14: TGT) inhibitors Vivolux AB...
BioCentury | Mar 3, 2014
Clinical News

Vivolux preclinical data

...or total protein. Additionally, in vitro, VLX600 reduced the viability of quiescent tumor cells, which Vivolux...
...in June. VLX600 is a small molecule that inhibits mitochondrial oxidative phosphorylation in hypoglycemic cells. Vivolux AB...
BioCentury | Dec 8, 2011
Targets & Mechanisms

Proteasome DUBstep

...inhibitor for cancer that has a distinct mechanism from other compounds in the class. 1 Vivolux AB...
...peptidase 7 ( USP7 ; HAUSP ) that is in preclinical development for cancer. Viva Vivolux...
...the sale, Ågerup's holding company, Lyftet Holding, owned 47.5% of Q-Med. Hans Rosén, CEO of Vivolux...
BioCentury | Nov 17, 2011
Distillery Therapeutics

Indication: Cancer

...solid tumors. SciBX 4(45); doi:10.1038/scibx.2011.1262 Published online Nov. 17, 2011 Patent application filed; licensed to Vivolux AB...
BioCentury | Nov 14, 2011
Financial News

Vivolux completes venture financing

Vivolux AB , Uppsala, Sweden Business: Cancer Date completed: 11/7/11 Type: Venture financing Raised: Not disclosed Investor: NXT2B WIR Staff cancer...
Items per page:
1 - 5 of 5